Elicio Therapeutics director Assaf Segal resigns effective August 28, 2023

Elicio Therapeutics, Inc.

Assaf Segal resigned from the Board of Elicio Therapeutics, effective immediately on August 28, 2023.
Resignation follows his planned departure as CEO of Clal Biotechnology Industries, not due to any disagreement.
No replacement named; the Board continues with remaining members.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Assaf Segal

Director

ELTX · Elicio Therapeutics, Inc.

Effective: 2023-08-28
Filed: August 30, 2023, 7:59 PM ET

On August 28, 2023, Assaf Segal submitted his resignation from the Board of Directors (the “Board”) of Elicio Therapeutics, Inc. (the “Company”), which resignation was effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Assaf Segal resigned as Director at Elicio Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 28, 2023, Assaf Segal submitted his resignation from the Board of Directors (the “Board”) of Elicio Therapeutics, Inc. (the “Company”), which resignation was effective immediately.

View on SEC.gov

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-23-000055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.